title: Cervical stromal involvement can predict survival in advanced endometrial carcinoma: a review of 67 patients.
abstract: OBJECTIVE
  To assess clinical, surgical and pathologic variables in survival of advanced endometrial cancer.
  
  
  METHODS
  Sixty-seven advanced-stage (stages III and IV according to FIGO 2009) endometrial cancer cases were evaluated retrospectively. The effects on survival of age, histologic subtype, stage, grade, myometrial invasion, optimal cytoreduction, parity and cervical involvement were analyzed.
  
  
  RESULTS
  Cervical involvement (P = 0.033) and nulliparity (P = 0.042) were worsening features in terms of survival. In 56 cases (83.5%) optimal cytoreduction could be achieved and survival was significantly longer in this group than the group who were not optimally cytoreduced (mean 30.4 vs. 9.6 months) (P < 0.01). Depth of myometrial invasion, histologic type of tumor, stage, grade, and age younger or older than 60 years were not found to be related to survival. Neither adjuvant therapy type nor their combination were superior to each other for improving survival.
  
  
  CONCLUSIONS
  Cervical stromal involvement is a poor prognostic factor in cases of advanced endometrial carcinoma. Further studies are required to describe the effect of different surgical approaches such as radical hysterectomy on survival in the presence of cervical stromal invasion.
authors.affiliation: Department of Obstetrics and Gynecology, Medical School of Ankara University, Ankara, Turkey. salihtaskin@yahoo.com
authors.forename: Salih
authors.initials: S
authors.lastname: Taşkın
authors.forename: Fırat
authors.initials: F
authors.lastname: Ortaç
authors.forename: Korhan
authors.initials: K
authors.lastname: Kahraman
authors.forename: Göksu
authors.initials: G
authors.lastname: Göç
authors.forename: Derya
authors.initials: D
authors.lastname: Oztuna
authors.forename: Mete
authors.initials: M
authors.lastname: Güngör
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000401:mortality* / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D009367:Neoplasm Staging; D011247:Pregnancy; D011379:Prognosis; D012189:Retrospective Studies; D017154:Stromal Cells / Q000473:pathology*
references.citation: Gynecol Oncol. 1984 Jan;17(1):64-74
references.pmid: 6693053
references.citation: J Clin Oncol. 2006 Jan 1;24(1):36-44
references.pmid: 16330675
references.citation: Int J Clin Oncol. 2009 Aug;14(4):344-50
references.pmid: 19705246
references.citation: Int J Radiat Oncol Biol Phys. 1989 Jul;17(1):35-9
references.pmid: 2745205
references.citation: Gynecol Oncol. 2009 Jun;113(3):316-23
references.pmid: 19345400
references.citation: Gynecol Oncol. 2000 Aug;78(2):85-91
references.pmid: 10926785
references.citation: Int J Gynecol Cancer. 2009 May;19(4):665-9
references.pmid: 19509568
references.citation: Br J Cancer. 2006 Aug 7;95(3):266-71
references.pmid: 16868539
references.citation: Gynecol Oncol. 2009 Mar;112(3):517-20
references.pmid: 19117598
references.citation: J Korean Med Sci. 2010 Apr;25(4):552-6
references.pmid: 20357997
references.citation: Int J Gynecol Cancer. 2002 Sep-Oct;12(5):448-53
references.pmid: 12366661
references.citation: Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1648-55
references.pmid: 16884379
references.citation: Gynecol Oncol. 1997 Oct;67(1):56-60
references.pmid: 9345357
references.citation: Gynecol Oncol. 1994 Dec;55(3 Pt 1):363-7
references.pmid: 7835775
references.citation: Gynecol Oncol. 1990 Aug;38(2):210-5
references.pmid: 2387538
references.citation: Gynecol Oncol. 1994 Feb;52(2):237-40
references.pmid: 8314145